Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7422288 | 0.86 | ADAMTS5 (0.48) | CYP2C9CYP2C19CYP3A4CYP2D6NPSR1 | |
| SCHEMBL7422284 | 0.86 | ADAMTS5 (0.48) | CYP2C9CYP2C19CYP3A4CYP2D6NPSR1 | |
| SCHEMBL28471853 | 0.81 | CYP3A4 (0.44) | TSHRCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL30441399 | 0.81 | CYP3A4 (0.44) | TSHRCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL27848685 | 0.80 | CYP3A4 (0.43) | TSHRCYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL7062171 | 0.80 | PER2 (0.46) | TSHRNPSR1POLBMEN1KMT2A | |
| SCHEMBL7062170 | 0.80 | PER2 (0.46) | TSHRNPSR1POLBMEN1KMT2A | |
| SCHEMBL18762444 | 0.79 | CYP3A4 (0.45) | CYP2C9CYP2C19CYP3A4CYP2D6NPSR1 | |
| SCHEMBL18762590 | 0.79 | CYP3A4 (0.45) | CYP2C9CYP2C19CYP3A4CYP2D6NPSR1 | |
| Sulfuric Acid SCHEMBL9194283 | 0.78 | BLM (0.41) | TSHRCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238020-B2 | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130089504-A1 | Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011133178-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED TAPENTADOL PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133179-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089504-A1 | Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug | TMPRSS15, DNPEP, PGA5 | TSHR 2638/4885CYP2C9 372/4885CYP2C19 578/4885 |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | CYP2C9, ACHE, COMT | TSHR 2444/4885CYP2C9 1/4885CYP2C19 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.